Participate in a T1D Clinical Trial in Northern California

Northern California Chapters

Participating in a clinical trial is a great way to contribute to curing, preventing, and treating type 1 diabetes (T1D) and its complications. Learn more below about the clinical trials currently recruiting in your area as well as Breakthrough T1D's easy tool to match you with a clinical trial in 60 seconds.

Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing and treating T1D. There are many opportunities in the Northern California area to participate in a T1D clinical trial close to home. You can check out local and virtual clinical trials presently recruiting in the section below. Additionally, Breakthrough T1D has an easy-to-use tool called the Clinical Trials Connection where you can match with a clinical trial in 60 seconds. It asks users some simple questions about themselves before matching them with trials for which they are eligible. Clinical Trials Connection uses your city, distance you’re willing to travel and other characteristics to narrow down hundreds of trials to the ones in which you might be interested. Start your search by visiting breakthrought1d.org/impact/research/clinical-trials today!

Quick Flyer Links:

Currently Recruiting Disease-Modifying Therapy Clinical Trials

Currently Recruiting Cell Therapy Clinical Trials

Currently Recruiting Virtual Clinical Trials

If you have any questions, please contact Jennifer Pliner, Breakthrough T1D Outreach Coordinator for Northern California, at [email protected].

FEATURED T1D STUDIES IN NORTHERN CALIFORNIA

VIRTUAL

Sanofi is sponsoring the TEPLI-Quest study to better understand the real-world experiences of those affected by Stage 2 T1D. Your or your child’s de-identified data helps inform efforts to develop future treatments and improve care. Participate from home, share your data (no extra labs, procedures, or in-person study visits), earn up to $495 in compensation for your time, 5 year study.

TIDES – 2 is a survey to learn about how teens with type I diabetes respond to a questionnaire around eating and diabetes management. The study involves a one-time, virtual meeting to complete the questionnaire, participate in an interview, and respond to two surveys. Earn $50 via an e-gift card.

The HEARTS (Health-Related Thoughts and Social Experiences) study aims to help individuals cope with social aspects of health conditions, improve how they think and feel about themselves, and improve their quality of life through group therapy. Attend virtual group meetings and complete questionnaires about how your health affects your mental health and quality of life. Receive $50 for completion of online questionnaires twice during the study, for a total of up to $100.

Researchers at UCSF are participating in the Commercial or Open Source Closed Loop Impact on Pregnancy (COSCLIP) Study. COSCLIP is a nationwide study of pregnant people with type 1 diabetes who use automated insulin delivery (AID) systems for diabetes management in pregnancy. Participants will be asked to remotely share their AID system data with the research team and complete online surveys regarding behavioral and emotional health.

Researchers at Stanford are conducting The Diabetes Wellness Teen Study, investigating risk factors that predict the future onset of body image and eating behavior concerns in adolescents with type 1 diabetes. Female-identifying individuals who have type 1 diabetes and are using a continuous glucose monitor are invited to participate. Participants can earn up to $125 over the course of the study!

Trial Net screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D,  between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.

Autoimmunity Screening for Kids (ASK) A research program offering SCREENINGS AT NO COST to ALL U.S. children (ages 1-17) and adults to detect Type 1 Diabetes and Celiac.

The T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for research (for example, by answering questions in annual surveys). Once enrolled, Registry participants can sign up for other studies on various topics related to type 1 diabetes.

NEWLY DIAGNOSED

The SAFEGUARD (SAB-142) study evaluates if SAB-142 (a new immunotherapy) can slow the progression of Stage 3 New Onset T1D. The trial involves a series of infusions, blood draws, and repeat meal tests to track natural insulin production over ~2 years. Benefits include potential preservation of C-peptide (natural insulin) as well as travel and time reimbursement.

The Wave – ATG with Verapamil study investigates if a 2-drug approach (low-dose ATG followed by 12 months of Adalimumab, Verapamil, or placebo) can stop the immune attack and preserve insulin production. Commitment includes screening, 2 infusions of ATG, and follow-up maintenance therapy over ~2 years, with the potential to extend the honeymoon phase along with travel/time reimbursement.

The Beta Preserve study tests whether TZIELD (Teplizumab) preserves remaining beta-cell function better than placebo in people recently diagnosed with Stage 3 T1D. Participants receive 12 consecutive daily infusions followed by regular monitoring over 52+ weeks for HbA1c, insulin requirements, and beta-cell function.

The POLARIS Study (A Study of GNTI-122 in Adults Recently Diagnosed with T1D) is recruiting participants ages 18 to 45 within 120 days of T1D diagnosis. This is a Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant’s own blood cells in adult participants with recently diagnosed T1D.

The COUR CNP-103 Study is recruiting participants ages 12 to 35 within 6 months (180 days) of T1D diagnosis. This study is a Phase 1b/2a First-in-Human clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-103.

MANAGEMENT

SUGARNSALT (Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease) is recruiting participants ages 18-75 living with T1D for at least 8 years with eGFR between 20-60 and urine ACR of 200+. Sotagliflozin has been shown to prevent or delay end-stage kidney disease in people with type 2 diabetes. This trial is investigating how these drugs work for people with T1D and safety of these drugs in the T1D population.

The INHALE-1st study evaluates the safety and efficacy of Afrezza® for youth with newly diagnosed type 1 diabetes in combination with basal insulin.

RESOURCES

What Are Clinical Trials Video

Clinical Trials and You Video

Match To Clinical Trials in 60 Seconds

Breakthrough T1D and Clinical Trials

TOPPLE Study Participant

Updated: September 4th, 2026

Learn more about clinical trials here: